Fat loss research examines peptides being studied for their potential effects on energy expenditure, appetite signalling, and lipid metabolism. This page reviews current scientific literature on peptide candidates for metabolic and body composition research.
Last updated: 24 April 2026
Fat loss research investigates GLP-1 analogues (semaglutide, tirzepatide, retatrutide) for appetite suppression and energy balance; AOD-9604 for direct lipolysis and metabolic rate; and MOTS-c for mitochondrial metabolic efficiency. Studies examine weight loss mechanisms, lean mass preservation, appetite satiety signalling, and cardiometabolic outcomes in obesity contexts.
GLP-1 RAs show the most robust evidence: semaglutide demonstrates sustained weight loss (10–22%) in large RCTs with cardiovascular benefits. Tirzepatide (GLP-1/GIP) shows superior weight loss (20–25%) in head-to-head trials. Retatrutide (GLP-1/GIP/GCG) shows promising early data. AOD-9604 research is more limited but suggests direct adipocyte lipolysis.
Most GLP-1 trials focus on diabetes populations; lean athlete use is underexplored. Long-term weight regain after cessation is common. Retatrutide human data are preliminary. Lean mass loss during GLP-1 therapy is debated and may require concurrent resistance training. Sustainability and adherence data are limited.
Semaglutide is ARTG-approved for type 2 diabetes and obesity (under approved medical supervision). Tirzepatide and retatrutide have different regulatory pathways; prescription requires specific medical indication. Off-label weight loss use in non-diabetic individuals is not TGA-approved. Supply must be through registered medical practitioners or institutional research.
Primary research interestMetabolic outcomes & incretin pathway analysis
Widely-prescribed GLP-1 receptor agonist with substantial trial evidence for weight loss and type 2 diabetes.
Primary research interestMetabolic outcomes & incretin pathway analysis
Dual GIP/GLP-1 receptor agonist with strong trial evidence for type 2 diabetes and weight management.
Primary research interestMetabolic outcomes & incretin pathway analysis
Next-generation triple hormone receptor agonist showing exceptional potential for weight loss and metabolic improvement.
Primary research interestMetabolic outcomes & incretin pathway analysis
GH fragment originally developed for fat loss; mixed clinical evidence.
Primary research interestCellular ageing & mitochondrial research
Mitochondrial-derived peptide studied for metabolic and longevity pathways.